Fibrillar tau alters cerebral endothelial cell metabolism, vascular inflammatory activation, and barrier function in vitro and in vivo
Alzheimer's & Dementia · 2025-03 · 21 (3)
DOI: 10.1002/alz.70077 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 20.03.2025. Verfasst von Roberto Guzmán-Hernández und 1 weiteren Autor:innen. Beteiligte Einrichtung: Alzheimer's Center at Temple, Department of Neural Sciences, Temple University Lewis Katz School of Medicine, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Blood-Brain Barrier, tau Proteins, Endothelial Cells, Brain. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIH HHS, Pennsylvania Department of Health Collaborative Research on Alzheimer's Disease (PA Cure), NIA NIH HHS.
Abstract (Originalsprache)
INTRODUCTION The presence of tau aggregates in and around the brain vasculature in Alzheimer's disease (AD) and tauopathies suggests its possible pathogenicity to cerebral endothelial cells (ECs). METHODS We used an in vitro model of the blood–brain barrier (BBB) to understand the mechanisms of fibrillar tau–mediated cerebral EC and BBB pathology, confirming our findings in 3‐month‐old P301S mice brains and extracted microvessels. RESULTS Protofibrillar and fibrillar tau species induce endothelial barrier permeability through an increase in glycolysis, which activates ECs toward a pro‐inflammatory phenotype, inducing loss of junction protein expression and localization. The Warburg‐like metabolic shift toward glycolysis and increased vascular pathological phenotypes are also present in young P301S mice. DISCUSSION In sum, our work reveals that fibrillar tau species, by enhancing endothelial glycolytic metabolism, promote vascular inflammatory phenotypes and loss of BBB function, highlighting the importance of addressing and targeting early tau‐mediated neurovascular damage in AD and tauopathies. Highlights We improve the understanding of the mechanisms of vascular pathology in tauopathies. Fibrillar tau mediates vascular metabolic changes, inflammation, and blood–brain barrier (BBB) dysfunction. These events are replicated at early stages in a tauopathy mouse model. Inhibiting altered glycolysis reduces BBB permeability and endothelial activation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Alzheimer's Center at Temple, Department of Neural Sciences, Temple University Lewis Katz School of Medicine, Philadelphia, Pennsylvania, USA.
Förderung
- NIH HHS
- Pennsylvania Department of Health Collaborative Research on Alzheimer's Disease (PA Cure)
- NIA NIH HHS
- NINDS NIH HHS
- Pennsylvania Department of Health
- National Institutes of Health
- National Institute of Neurological Disorders and Stroke
- National Institute on Aging
Zitieren
APA
Guzmán-Hernández, R., & Fossati, S. (2025). Fibrillar tau alters cerebral endothelial cell metabolism, vascular inflammatory activation, and barrier function in vitro and in vivo. Alzheimer's & Dementia, 21(3). https://doi.org/10.1002/alz.70077
Vancouver
Guzmán-Hernández R, Fossati S. Fibrillar tau alters cerebral endothelial cell metabolism, vascular inflammatory activation, and barrier function in vitro and in vivo. Alzheimer's & Dementia. 2025;21(3). doi:10.1002/alz.70077
BibTeX
@article{GuzmnHernndez2025,
author = {Guzmán-Hernández, Roberto and Fossati, Silvia},
title = {Fibrillar tau alters cerebral endothelial cell metabolism, vascular inflammatory activation, and barrier function in vitro and in vivo},
journal = {Alzheimer's & Dementia},
year = {2025},
volume = {21},
number = {3},
doi = {10.1002/alz.70077}
}
EUVIMED